Methods of inhibiting ECM accumulation in the CNS by inhibition of TGF-.beta.

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5958411
SERIAL NO

08410573

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods for preventing, suppressing or treating a CNS pathology characterized by a deleterious accumulation of extracellular matrix in a tissue by contacting the tissue with an agent that inhibits the extracellular matrix producing activity of TGF-.beta.. The methods can be used to prevent, suppress or treat scar formation in the CNS. Agents that are useful in the present methods include neutralizing anti-TGF-.beta. antibodies, Arg-Gly-Asp-containing peptides, decorin and its functional equivalents such as biglycan, and TGF-.beta. antagonists. The present invention further provides methods for preventing, suppressing or treating a CNS pathology characterized by the insufficient accumulation of extracellular matrix. Agents that enhance the production of extracellular matrix, such as TGF-.beta., can be used in such methods. Finally, the present invention provides pharmaceutical compositions containing these agents, which can be administered to patients to inhibit or enhance the production of extracellular matrix in the CNS.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
CAMBRIDGE ANTIBODY TECHNOLOGY LIMITEDROYSTON CAMBRIDGESHIRE SG8 6JJ

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baird, Andrew San Diego, CA 55 1099
Logan, Ann Worcestershire, GB 11 188

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation